Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KLRS
KALARIS THERAPEUTICS INC
NASDAQ
$4.03
▼ DOWN 1.71% (-0.07)

KEY STATISTICS

Market Cap$87.96 M
52w High$11.88
52w Low$3.03
Dividend Yield—
Frequency—
P/E-2.00
Volume52.61K
Shares Out.21.83M

COMPANY

LEADERSHIP

Andrew Oxtoby
CHIEF EXECUTIVE
Andrew Oxtoby

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 30, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
20

PRICE TARGET

Target High$23.00
Target Low$14.00
Target Median$17.00
Target Consensus$18.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2025-01-16Reverse1:23

PRICE

$4.03 ▼ DOWN 1.71% (−$0.07)
OVERLAYS
$3.90$4.00$4.10$4.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.03

About Kalaris Therapeutics Inc

https://kalaristx.com ↗

Kalaris Therapeutics Inc develops novel cell therapies to restore natural immunity against life-threatening virus-related diseases in immunocompromised patients.

INDUSTRY

Biotechnology

A PRODUCT KALARIS THERAPEUTICS INC IS KNOWN FOR

TH103
TH103

TH103 is a clinical-stage, fully humanized fusion protein designed for intravitreal injection to inhibit VEGF, targeting neovascular retinal diseases like nAMD, diabetic eye disease, and retinal vein occlusion.

COMPETITORS

COMPETITOR
KOD COMPARE
NVS COMPARE
OTLK COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
3
RANKED BY POSITION SIZE
VTS.AX
0.00% · 255.3K
IWC
0.01% · 26.3K
DCOR
0.00% · 3.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.53%
HOLDERS
62
TOP 12 OF 62 · RANKED BY POSITION SIZE
Samsara Biocapital, LLC
12.9M sh · $74.71M
Rtw Investments, LP
1.3M sh · $7.5M
Paradigm Biocapital Advisors LP
700.0K sh · $4.04M
Alyeska Investment Group, L.P.
572.7K sh · $3.27M
Siren, L.L.C.
435.8K sh · $2.51M
Tang Capital Management LLC
418.2K sh · $2.42M
Ikarian Capital, LLC
360.0K sh · $2.08M
Propel Bio Management, LLC
295.8K sh · $1.72M
Vanguard Group Inc
292.8K sh · $2.47M
Woodline Partners LP
241.1K sh · $1.39M
Raymond James Financial Inc
118.9K sh · $685.98K
Renaissance Technologies LLC
112.8K sh · $651.7K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: VP, CORPORATE CONTROLLER
Vandekop Amy O'Leary
Purchase · 10.0K shares
2026-08-27
★
DIRECTOR
KEATING LAURIE
Purchase · 18.0K shares
2026-08-01
★
KEATING LAURIE
— · —
2026-08-01
★
OFFICER: SEE REMARKS
Vandekop Amy O'Leary
— · 27.4K shares
2026-07-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET OUTPERFORM 1
1 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
ARTV$11.09COMPARE
OVID$2.80COMPARE
IFRX$2.23COMPARE
STRO$20.45COMPARE
CNTB$2.23COMPARE
IMA$5.34COMPARE
MGX$1.19COMPARE